Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

A phase I trial of the ╬│-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.

Cook N, Basu B, Smith DM, Gopinathan A, Evans J, Steward WP, Palmer D, Propper D, Venugopal B, Hategan M, Anthoney DA, Hampson LV, Nebozhyn M, Tuveson D, Farmer-Hall H, Turner H, McLeod R, Halford S, Jodrell D.

Br J Cancer. 2018 Mar 20;118(6):793-801. doi: 10.1038/bjc.2017.495. Epub 2018 Feb 13.

2.

Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice.

Cai H, Scott E, Kholghi A, Andreadi C, Rufini A, Karmokar A, Britton RG, Horner-Glister E, Greaves P, Jawad D, James M, Howells L, Ognibene T, Malfatti M, Goldring C, Kitteringham N, Walsh J, Viskaduraki M, West K, Miller A, Hemingway D, Steward WP, Gescher AJ, Brown K.

Sci Transl Med. 2015 Jul 29;7(298):298ra117. doi: 10.1126/scitranslmed.aaa7619.

3.

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.

Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA.

Lancet Oncol. 2015 Aug;16(8):967-78. doi: 10.1016/S1470-2045(15)00139-4. Epub 2015 Jul 12. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427.

4.

Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy.

James MI, Iwuji C, Irving G, Karmokar A, Higgins JA, Griffin-Teal N, Thomas A, Greaves P, Cai H, Patel SR, Morgan B, Dennison A, Metcalfe M, Garcea G, Lloyd DM, Berry DP, Steward WP, Howells LM, Brown K.

Cancer Lett. 2015 Aug 10;364(2):135-41. doi: 10.1016/j.canlet.2015.05.005. Epub 2015 May 12.

5.

Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial.

Irving GR, Iwuji CO, Morgan B, Berry DP, Steward WP, Thomas A, Brown K, Howells LM.

Trials. 2015 Mar 24;16:110. doi: 10.1186/s13063-015-0641-1.

6.

Characterization and propagation of tumor initiating cells derived from colorectal liver metastases: trials, tribulations and a cautionary note.

James MI, Howells LM, Karmokar A, Higgins JA, Greaves P, Cai H, Dennison A, Metcalfe M, Garcea G, Lloyd DM, Berry DP, Steward WP, Brown K.

PLoS One. 2015 Feb 6;10(2):e0117776. doi: 10.1371/journal.pone.0117776. eCollection 2015.

7.

Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.

Le Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward WP, Gronchi A, Hogendoorn PC, Litiere S, Marreaud S, Blay JY, Van Der Graaf WT.

Ann Oncol. 2014 Dec;25(12):2425-32. doi: 10.1093/annonc/mdu460. Epub 2014 Oct 6.

PMID:
25294887
8.

Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies.

Haqq J, Howells LM, Garcea G, Metcalfe MS, Steward WP, Dennison AR.

Eur J Cancer. 2014 Oct;50(15):2570-82. doi: 10.1016/j.ejca.2014.06.021. Epub 2014 Aug 1. Review.

PMID:
25091797
9.

Translating curcumin to the clinic for lung cancer prevention: evaluation of the preclinical evidence for its utility in primary, secondary, and tertiary prevention strategies.

Howells LM, Mahale J, Sale S, McVeigh L, Steward WP, Thomas A, Brown K.

J Pharmacol Exp Ther. 2014 Sep;350(3):483-94. doi: 10.1124/jpet.114.216333. Epub 2014 Jun 17. Review.

10.

Cellular and plasma uptake of parenteral omega-3 rich lipid emulsion fatty acids in patients with advanced pancreatic cancer.

Arshad A, Chung WY, Isherwood J, Mann CD, Al-Leswas D, Steward WP, Metcalfe MS, Dennison AR.

Clin Nutr. 2014 Oct;33(5):895-9. doi: 10.1016/j.clnu.2013.09.017. Epub 2013 Oct 6.

PMID:
24140233
11.

Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence.

Patel KR, Andreadi C, Britton RG, Horner-Glister E, Karmokar A, Sale S, Brown VA, Brenner DE, Singh R, Steward WP, Gescher AJ, Brown K.

Sci Transl Med. 2013 Oct 2;5(205):205ra133. doi: 10.1126/scitranslmed.3005870.

12.

Changing trends in the presentation of colorectal liver metastases in a single hepatobiliary tertiary referral centre over fourteen years.

Thomasset SC, Dennison AR, Metcalfe MS, Steward WP, Garcea G.

Eur J Surg Oncol. 2013 Nov;39(11):1243-7. doi: 10.1016/j.ejso.2013.08.021. Epub 2013 Sep 7.

PMID:
24055380
13.

Comet assay measures of DNA damage are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo.

Bowman KJ, Al-Moneef MM, Sherwood BT, Colquhoun AJ, Goddard JC, Griffiths TR, Payne D, Singh S, Butterworth PC, Khan MA, Summerton DJ, Steward WP, McKelvey-Martin VJ, McKeown SR, Kockelbergh RC, Mellon JK, Symonds RP, Jones GD.

Int J Cancer. 2014 Mar 1;134(5):1102-11. doi: 10.1002/ijc.28437. Epub 2013 Oct 8.

14.

The role of cancer stem cells in the anti-carcinogenicity of curcumin.

Norris L, Karmokar A, Howells L, Steward WP, Gescher A, Brown K.

Mol Nutr Food Res. 2013 Sep;57(9):1630-7. doi: 10.1002/mnfr.201300120. Epub 2013 Jul 31. Review.

PMID:
23900994
15.

Resveratrol in the management of human cancer: how strong is the clinical evidence?

Gescher A, Steward WP, Brown K.

Ann N Y Acad Sci. 2013 Jul;1290:12-20. doi: 10.1111/nyas.12205. Review.

PMID:
23855461
16.

Cancer chemoprevention: a rapidly evolving field.

Steward WP, Brown K.

Br J Cancer. 2013 Jul 9;109(1):1-7. doi: 10.1038/bjc.2013.280. Epub 2013 Jun 4. Review.

17.

Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration--a clinical pilot study including assessment of patient acceptability.

Irving GR, Howells LM, Sale S, Kralj-Hans I, Atkin WS, Clark SK, Britton RG, Jones DJ, Scott EN, Berry DP, Hemingway D, Miller AS, Brown K, Gescher AJ, Steward WP.

Cancer Prev Res (Phila). 2013 Feb;6(2):119-28. doi: 10.1158/1940-6207.CAPR-12-0281. Epub 2012 Dec 11.

18.

Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.

Britton RG, Horner-Glister E, Pomenya OA, Smith EE, Denton R, Jenkins PR, Steward WP, Brown K, Gescher A, Sale S.

Eur J Med Chem. 2012 Aug;54:952-8. doi: 10.1016/j.ejmech.2012.06.031. Epub 2012 Jun 22.

PMID:
22789812
19.

Dietary intake of rosmarinic acid by Apc(Min) mice, a model of colorectal carcinogenesis: levels of parent agent in the target tissue and effect on adenoma development.

Karmokar A, Marczylo TH, Cai H, Steward WP, Gescher AJ, Brown K.

Mol Nutr Food Res. 2012 May;56(5):775-83. doi: 10.1002/mnfr.201100617.

PMID:
22648624
20.

Tissue distribution and metabolism of the putative cancer chemopreventive agent 3',4',5'-trimethoxyflavonol (TMFol) in mice.

Saad SE, Jones DJ, Norris LM, Horner-Glister E, Patel KR, Britton RG, Steward WP, Gescher AJ, Brown K, Sale S.

Biomed Chromatogr. 2012 Dec;26(12):1559-66. doi: 10.1002/bmc.2732. Epub 2012 Mar 27.

PMID:
22454297
21.

Resveratrol in human cancer chemoprevention--choosing the 'right' dose.

Scott E, Steward WP, Gescher AJ, Brown K.

Mol Nutr Food Res. 2012 Jan;56(1):7-13. doi: 10.1002/mnfr.201100400. Epub 2011 Oct 7. Review.

PMID:
22218912
22.

Curcumin: the potential for efficacy in gastrointestinal diseases.

Irving GR, Karmokar A, Berry DP, Brown K, Steward WP.

Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):519-34. doi: 10.1016/j.bpg.2011.09.005. Review.

PMID:
22122768
23.

Evaluation of urinary ribonucleoside profiling for clinical biomarker discovery using constant neutral loss scanning liquid chromatography/tandem mass spectrometry.

Teichert F, Winkler S, Keun HC, Steward WP, Gescher AJ, Farmer PB, Singh R.

Rapid Commun Mass Spectrom. 2011 Jul 30;25(14):2071-82. doi: 10.1002/rcm.5086.

PMID:
21698690
24.

Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics.

Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, Brown K, Steward WP, Gescher AJ.

Cancer Prev Res (Phila). 2011 Sep;4(9):1419-25. doi: 10.1158/1940-6207.CAPR-11-0148. Epub 2011 Jun 16.

25.

Pooled survival and response data from phase III randomized controlled trials for gemcitabine-based regimes in the treatment of advanced pancreatic cancer.

Arshad A, Al-Leswas D, Al-Taan O, Stephenson J, Metcalfe M, Steward WP, Dennison AR.

Am J Clin Oncol. 2013 Aug;36(4):411-4. doi: 10.1097/COC.0b013e3182124216. Review.

PMID:
21436672
26.

Clinical trials of resveratrol.

Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K.

Ann N Y Acad Sci. 2011 Jan;1215:161-9. doi: 10.1111/j.1749-6632.2010.05853.x. Review.

PMID:
21261655
27.

Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis.

Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, Brenner DE.

Cancer Res. 2010 Nov 15;70(22):9003-11. doi: 10.1158/0008-5472.CAN-10-2364. Epub 2010 Oct 8.

28.

Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients.

Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, Brenner DE, Steward WP, Gescher AJ, Brown K.

Cancer Res. 2010 Oct 1;70(19):7392-9. doi: 10.1158/0008-5472.CAN-10-2027. Epub 2010 Sep 14.

29.

Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo.

Howells LM, Sale S, Sriramareddy SN, Irving GR, Jones DJ, Ottley CJ, Pearson DG, Mann CD, Manson MM, Berry DP, Gescher A, Steward WP, Brown K.

Int J Cancer. 2011 Jul 15;129(2):476-86. doi: 10.1002/ijc.25670. Epub 2010 Nov 3.

30.

Determination of anthocyanins in the urine of patients with colorectal liver metastases after administration of bilberry extract.

Cai H, Thomasset SC, P-Berry D, Garcea G, Brown K, Steward WP, Gescher AJ.

Biomed Chromatogr. 2011 Jun;25(6):660-3. doi: 10.1002/bmc.1499. Epub 2010 Aug 31.

PMID:
20812200
31.

Development of a targeted adductomic method for the determination of polycyclic aromatic hydrocarbon DNA adducts using online column-switching liquid chromatography/tandem mass spectrometry.

Singh R, Teichert F, Seidel A, Roach J, Cordell R, Cheng MK, Frank H, Steward WP, Manson MM, Farmer PB.

Rapid Commun Mass Spectrom. 2010 Aug 30;24(16):2329-40. doi: 10.1002/rcm.4645.

PMID:
20658679
32.

Preclinical colorectal cancer chemopreventive efficacy and p53-modulating activity of 3',4',5'-trimethoxyflavonol, a quercetin analogue.

Howells LM, Britton RG, Mazzoletti M, Greaves P, Broggini M, Brown K, Steward WP, Gescher AJ, Sale S.

Cancer Prev Res (Phila). 2010 Aug;3(8):929-39. doi: 10.1158/1940-6207.CAPR-09-0236. Epub 2010 Jul 13.

33.

Plasma metabolic profiling reveals age-dependency of systemic effects of green tea polyphenols in mice with and without prostate cancer.

Teichert F, Verschoyle RD, Greaves P, Jones DJ, Wilson ID, Farmer PB, Steward WP, Gescher AJ, Keun HC.

Mol Biosyst. 2010 Oct;6(10):1911-6. doi: 10.1039/c004702c. Epub 2010 Jun 25.

PMID:
20577699
34.

Pharmacokinetics in mice and metabolism in murine and human liver fractions of the putative cancer chemopreventive agents 3',4',5',5,7-pentamethoxyflavone and tricin (4',5,7-trihydroxy-3',5'-dimethoxyflavone).

Cai H, Sale S, Britton RG, Brown K, Steward WP, Gescher AJ.

Cancer Chemother Pharmacol. 2011 Feb;67(2):255-63. doi: 10.1007/s00280-010-1313-1. Epub 2010 Apr 4.

PMID:
20364427
35.

Anthocyanin-rich red grape extract impedes adenoma development in the Apc(Min) mouse: pharmacodynamic changes and anthocyanin levels in the murine biophase.

Cai H, Marczylo TH, Teller N, Brown K, Steward WP, Marko D, Gescher AJ.

Eur J Cancer. 2010 Mar;46(4):811-7. doi: 10.1016/j.ejca.2009.12.017. Epub 2010 Jan 7.

PMID:
20060287
36.

APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the Apc(Min) mouse model in vivo.

Sale S, Fong IL, de Giovanni C, Landuzzi L, Brown K, Steward WP, Gescher AJ.

Eur J Cancer. 2009 Nov;45(16):2731-5. doi: 10.1016/j.ejca.2009.07.004. Epub 2009 Aug 18.

PMID:
19695862
37.

A fuller understanding of pancreatic neuroendocrine tumours combined with aggressive management improves outcome.

Ong SL, Garcea G, Pollard CA, Furness PN, Steward WP, Rajesh A, Spencer L, Lloyd DM, Berry DP, Dennison AR.

Pancreatology. 2009;9(5):583-600. doi: 10.1159/000212085. Epub 2009 Aug 4. Review.

PMID:
19657214
38.

Flavones as colorectal cancer chemopreventive agents--phenol-o-methylation enhances efficacy.

Cai H, Sale S, Schmid R, Britton RG, Brown K, Steward WP, Gescher AJ.

Cancer Prev Res (Phila). 2009 Aug;2(8):743-50. doi: 10.1158/1940-6207.CAPR-09-0081. Epub 2009 Jul 28.

39.

Surgical bypass vs. endoscopic stenting for pancreatic ductal adenocarcinoma.

Scott EN, Garcea G, Doucas H, Steward WP, Dennison AR, Berry DP.

HPB (Oxford). 2009 Mar;11(2):118-24. doi: 10.1111/j.1477-2574.2008.00015.x.

40.

Pilot study of oral anthocyanins for colorectal cancer chemoprevention.

Thomasset S, Berry DP, Cai H, West K, Marczylo TH, Marsden D, Brown K, Dennison A, Garcea G, Miller A, Hemingway D, Steward WP, Gescher AJ.

Cancer Prev Res (Phila). 2009 Jul;2(7):625-33. doi: 10.1158/1940-6207.CAPR-08-0201.

41.

Determination of 5-methyl-2'-deoxycytidine in genomic DNA using high performance liquid chromatography-ultraviolet detection.

Sandhu J, Kaur B, Armstrong C, Talbot CJ, Steward WP, Farmer PB, Singh R.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 1;877(20-21):1957-61. doi: 10.1016/j.jchromb.2009.05.032. Epub 2009 May 21.

PMID:
19501556
42.

Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials.

Scott EN, Gescher AJ, Steward WP, Brown K.

Cancer Prev Res (Phila). 2009 Jun;2(6):525-30. doi: 10.1158/1940-6207.CAPR-08-0223. Epub 2009 May 26. Review.

43.

Evaluation of the DNA damaging potential of cannabis cigarette smoke by the determination of acetaldehyde derived N2-ethyl-2'-deoxyguanosine adducts.

Singh R, Sandhu J, Kaur B, Juren T, Steward WP, Segerb├Ąck D, Farmer PB.

Chem Res Toxicol. 2009 Jun;22(6):1181-8. doi: 10.1021/tx900106y.

PMID:
19449825
44.

Pharmacokinetics and metabolism of the putative cancer chemopreventive agent cyanidin-3-glucoside in mice.

Marczylo TH, Cooke D, Brown K, Steward WP, Gescher AJ.

Cancer Chemother Pharmacol. 2009 Nov;64(6):1261-8. doi: 10.1007/s00280-009-0996-7. Epub 2009 Apr 11.

PMID:
19363608
45.

Do anthocyanins and anthocyanidins, cancer chemopreventive pigments in the diet, merit development as potential drugs?

Thomasset S, Teller N, Cai H, Marko D, Berry DP, Steward WP, Gescher AJ.

Cancer Chemother Pharmacol. 2009 Jun;64(1):201-11. doi: 10.1007/s00280-009-0976-y. Epub 2009 Mar 18. Review.

PMID:
19294386
46.

Synthesis of the flavonoid 3',4',5'-trimethoxyflavonol and its determination in plasma and tissues of mice by HPLC with fluorescence detection.

Britton RG, Fong I, Saad S, Brown K, Steward WP, Gescher A, Sale S.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Apr 1;877(10):939-42. doi: 10.1016/j.jchromb.2009.02.043. Epub 2009 Feb 24.

PMID:
19282252
47.

Rapid analysis of curcumin and curcumin metabolites in rat biomatrices using a novel ultraperformance liquid chromatography (UPLC) method.

Marczylo TH, Steward WP, Gescher AJ.

J Agric Food Chem. 2009 Feb 11;57(3):797-803. doi: 10.1021/jf803038f.

PMID:
19152267
48.

Determination of 8-oxo-2'-deoxyguanosine and creatinine in murine and human urine by liquid chromatography/tandem mass spectrometry: application to chemoprevention studies.

Teichert F, Verschoyle RD, Greaves P, Thorpe JF, Mellon JK, Steward WP, Farmer PB, Gescher AJ, Singh R.

Rapid Commun Mass Spectrom. 2009 Jan;23(2):258-66. doi: 10.1002/rcm.3873. Erratum in: Rapid Commun Mass Spectrom. 2010 Jul;24(14):2175.

PMID:
19072863
49.

Simultaneous determination of 8-oxo-2'-deoxyguanosine and 8-oxo-2'-deoxyadenosine in DNA using online column-switching liquid chromatography/tandem mass spectrometry.

Singh R, Teichert F, Verschoyle RD, Kaur B, Vives M, Sharma RA, Steward WP, Gescher AJ, Farmer PB.

Rapid Commun Mass Spectrom. 2009 Jan;23(1):151-60. doi: 10.1002/rcm.3866.

PMID:
19065576
50.

Prognostic molecular markers in cholangiocarcinoma: a systematic review.

Briggs CD, Neal CP, Mann CD, Steward WP, Manson MM, Berry DP.

Eur J Cancer. 2009 Jan;45(1):33-47. doi: 10.1016/j.ejca.2008.08.024. Epub 2008 Oct 18. Review.

PMID:
18938071

Supplemental Content

Loading ...
Support Center